Parker Institute for Cancer Immunotherapy
Chris Cabanski, PhD, is Senior Director, Network Clinical Research at PICI. He is responsible for engaging with the PICI Network and PICI collaboration partners on emerging clinical research and facilitating the clinical trial design and operation of such investigator-sponsored research in multi-center settings.
Cabanski’s career interests include clinical trial design, data visualization and biomarker analysis. He previously led the biostatistics, data management and clinical science groups that were responsible for the collection, analysis and interpretation of clinical data for all PICI-sponsored trials. Prior to PICI, he worked as a senior biostatistician at Genentech, where he helped develop several early-stage molecules across various immunological diseases including asthma, idiopathic pulmonary fibrosis and chronic spontaneous urticaria. He completed postdoctoral training in the laboratory of Christopher Maher at The Genome Institute at Washington University School of Medicine in St. Louis, where he analyzed thousands of cancer transcriptomes to identify long noncoding RNAs (lncRNAs) that are commonly dysregulated across multiple cancer types.
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.